Changes reflect shifts in acquisition accounting or valuation of intangible assets rather than operational performance.
This represents specific accounting adjustments made to amortization expenses, often related to intangible assets acquir...
Company-specific; peers may include this within 'Amortization of Intangibles' or 'Operating Expenses'.
gild_adjustment_for_amortization| Segment | FY'21 | FY'22 |
|---|---|---|
| Covance Drug Development | $27.50M | $88.40 |
| Total | — | — |
All segment values are derived from annual filings.
Covance Drug Development was previously reported and has since been discontinued or reclassified. Only currently active segments are shown in the chart.